Esophageal cancer chemotherapy drug cis evaluation of uranium

By | March 19, 2012

Soon the evaluation of uranium, uranium along the most commonly used in clinical anticancer drug, and its broad spectrum anti-tumor, bone marrow suppression lighter, using a variety of tumors combined regimen has a good effect. Renal toxicity in recent years to resolve and gastrointestinal reactions, based on a number of refractory tumors and be effective as second-line rescue program.
Modern clinical research, Shen Mai injection can reduce chemotherapy-induced nausea and vomiting, and enhance the ondansetron and other drugs. Soon the evaluation of uranium, along with chemotherapy in the treatment of pan plus Shen Mai injection control nausea and vomiting, antiemetic efficacy to both strengthen the original, but also to prevent delayed vomiting after chemotherapy, and no obvious adverse effects, to improve the patients tolerance to chemotherapy and thus extend the survival of patients with good effect. In recent years the development of second generation lead lead Antitumor Nida, renal toxicity of lead than the smooth light, bone marrow suppression and thrombocytopenia is the dose-limiting toxicity.
Domestic and foreign clinical study confirmed that H, the drug head and neck squamous cell carcinoma, esophageal and cervical squamous cell carcinoma, which are better results. FukuchiM other 42 patients with advanced and unresectable patients with esophageal squamous cell carcinoma and 5-FU Nida sales combined with radiotherapy, 25 patients with unresectable tumors, and the other 17 cases received neoadjuvant treatment of unresectable synchronous release group chemotherapy. Radiation by 10 – 15MV photon beam radiation field II, daily 2Gy, 5 times a week, total 60 – 66Gy. Concurrent chemotherapy for the day 1 and day 29 intravenous Nida uranium 80mg/ml, the first 1-5 days, 29 – 33 days 5-FU350mg/ml continuous infusion. Evaluated after 2 weeks. 17 cases of neoadjuvant treatment group received 4 weeks of concurrent chemotherapy, external beam daily 2Gy, 5 times a week, total 40Gy, concurrent chemotherapy for the Nida intravenously on day 1 lead, 1 – 5 days applied 5-FU, dose and use the same front.
Evaluated 2 weeks after chemotherapy. 25 cases of unresectable patients, 22 were evaluable for efficacy, 2 of CR, 15 PR, 5 NC, overall response rate was 77%. Neoadjuvant chemotherapy group, 14 patients underwent surgery, 2 cases of preoperative CR, 10 of PR, 5 NC, 39 patients, overall response rate was 74%. After surgery in 14 patients, pathologic CR rate was 28.6%. 1 year and 2 year survival rates were 48.2% and 12.1%.
Soon the evaluation of uranium, Yamanaka et al reported that application of a little Nida Institute of lead and fluorouracil combination therapy of esophageal cancer in 17 cases, 2 cases of complete remission, partial remission in 11 cases, total effective rate 76.5%; Hirata et al reported that preoperative treatment with Nida lead 10 cases of esophageal cancer patients ,80-100mg / ml, 4 once a week to repeat a total of 2 cycles total effective rate was 30%, as observed with treatment-related serious adverse events, such as China Zhong-Zhen Guan joint lead with domestic Nida Well Court fluorouracil treatment of esophageal in 28 cases, total effective rate was 32.1%, that because of renal toxicity was mild Nida sales, is expected to replace the lead along a standard treatment of esophageal cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *